Trenbolone
Trenbolone acetate / enanthate; (Finaplix, Parabolan historically)
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No human medical approval; veterinary cattle-implant origin (Schedule III as an anabolic steroid)
- WADA
- Prohibited at all times (S1 Anabolic Agents).
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about trenbolone in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Trenbolone is a synthetic 19-nortestosterone derivative developed for veterinary use, as cattle-implant pellets (e.g., Finaplix) to increase feed efficiency and lean mass. It has never been approved for human medical use (a short-lived French human product, Parabolan, was discontinued). It binds the androgen receptor with roughly three times the affinity of testosterone, does not aromatize to estrogen, and has potent progestogenic activity. It is widely regarded in clinical and harm-reduction literature as high-risk because of pronounced cardiovascular, neuropsychiatric and renal concerns reported among users.
A cattle-growth implant with no approved human use, and one of the most harm-associated AAS.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
- No approved human indication
- Trenbolone has no FDA human approval. Its legitimate use is veterinary growth promotion; the brief French human product (Parabolan) was withdrawn.
How it is supposed to work
Trenbolone binds the androgen receptor with high affinity to drive muscle protein synthesis and nutrient partitioning. Because it does not aromatize, it produces no estrogenic effect directly, but its progestogenic activity contributes to suppression and side effects. Its potency and lack of conversion to weaker metabolites underlie both its perceived efficacy and its harm reputation.
A 19-nortestosterone (estrane) skeleton bearing additional conjugated double bonds (the 9,11-diene system) that raise androgen-receptor affinity and block aromatization. Marketed esters (acetate, enanthate, hexahydrobenzylcarbonate) alter duration of action.
Why it is treated as high-risk
Beyond standard AAS harms, trenbolone is associated in case reports and user surveys with prominent neuropsychiatric effects (insomnia, anxiety, aggression, night sweats), adverse cardiovascular and renal signals, and strong suppression. With no human pharmacovigilance, because it was never a human drug, users have no clinical dosing or safety data, only veterinary and anecdotal sources.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Trenbolone has no approved human use; self-administration carries documented and poorly characterized health risks.
- Marked neuropsychiatric effects reported: insomnia, anxiety, irritability/aggression, night sweats.
- Adverse cardiovascular signals; potent suppression of HDL.
- Renal concerns reported in case literature.
- Strong HPTA suppression and progestogenic side effects.
- No human dosing or safety data, only veterinary/anecdotal sources, plus counterfeit/conversion contamination risk.
Replacement is not the same as a cycle
There is no physiologic or therapeutic human dose of trenbolone, any human use is supraphysiological and unsanctioned. This entry documents the compound; it provides no dosing, conversion or cycle guidance.
What it does to fertility
Potent suppression of LH/FSH and spermatogenesis, compounded by progestogenic activity. Subfertility during use is expected; human recovery data are essentially absent.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Lipid panel
- Blood pressure
- Renal function
- Hematocrit
- LH/FSH, testosterone
- Mental-health assessment
What people get wrong
Often said'Trenbolone is the king of mass with no estrogen problems'
ActuallyIt does not aromatize, but its progestogenic activity, severe suppression, and reported cardiovascular, renal and neuropsychiatric effects make it among the most harm-associated AAS, not a 'cleaner' option.
Often said'It is safe because cattle get it'
ActuallyCattle implants are dosed for animals headed to slaughter under residue rules; this provides no human safety or dosing basis whatsoever.
Who profits, and who pushes back
Harm-reduction toxicologists
Regard trenbolone as among the highest-risk anabolic agents, citing concentrated cardiovascular, renal and neuropsychiatric reports despite the absence of controlled human data.
Regulatory pharmacologists
Note that trenbolone was never approved for human use and that veterinary-implant origin means no human safety dossier exists to characterize its risks.
Evidence-grading reviewers
Caution that much of the harm reputation rests on case reports and forum-derived accounts rather than controlled studies, so potency and danger claims carry low evidence certainty.
How we got here
Trenbolone was developed in the 1960s-70s and commercialized for livestock growth promotion (cattle-implant products such as Finaplix). A human formulation, Parabolan (trenbolone hexahydrobenzylcarbonate), was sold in France for wasting indications but was discontinued, leaving no legitimate human product. It entered illicit physique use partly by conversion of veterinary implant pellets.
- 1960s-70sTrenbolone developed and used for cattle growth promotion
- 1980s-90sParabolan (human) marketed in France, then discontinued
- PresentNo human medical approval; widely used illicitly and regarded as high-risk
Set against the alternatives
Among the three reference androgens, trenbolone sits at the high-potency, high-concern extreme: it binds the androgen receptor more strongly than testosterone or nandrolone, is neither aromatized nor 5-alpha-reduced, and adds pronounced progestogenic activity that nandrolone shows only moderately and testosterone essentially lacks. Where testosterone has a legitimate replacement indication and nandrolone a limited historical medical record, trenbolone has no human approval and originates as a cattle implant. The same non-aromatizing, non-reducing profile that users associate with potency also removes the milder metabolites that buffer testosterone, which clinicians link to its reputation for severe side effects. This entry is strictly documentary and provides no dosing guidance.
| Property | Testosterone | Nandrolone | Trenbolone |
|---|---|---|---|
| AR affinity | Reference (1x) | Higher than testosterone | Highest of the three |
| Aromatization | Aromatizes to estradiol | Minimal aromatization | Does not aromatize |
| 5-alpha reduction | To DHT (more potent) | To weaker metabolite | Not reduced |
| Progestogenic activity | Negligible | Notable | Pronounced |
| Human approval | Yes (TRT) | Historical/limited | None (veterinary origin) |
What we do not know
- What is the true cardiovascular and renal risk profile, given the absence of controlled human trials?
- How much of trenbolone's harm reputation reflects the drug versus polypharmacy in real users?
- What mechanisms drive its reported neuropsychiatric effects beyond generic androgen exposure?
- How does its pronounced progestogenic activity contribute to suppression and side effects quantitatively?
- Can metabolite or biomarker testing reliably detect use and exposure-related organ injury?
What could change
Forensic and harm-surveillance dataToxicology registries tracking trenbolone-associated presentationsMechanistic toxicity studiesIn-vitro and animal work on cardiac, renal and neural effectsDetection methodsImproved metabolite assays for use confirmationProgestogenic-pathway researchClarifying how progestin activity shapes its side-effect profile
At a glance
- Class
- 19-nortestosterone derivative (cattle-implant origin)
- Human approval
- None
- AR affinity
- ~3x testosterone (reported)
- Aromatization
- Does not aromatize; progestogenic
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Trenbolone. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Neil et al. / FDA veterinary safety reviews of trenbolone acetate implantsvarious
Establish trenbolone's veterinary-growth-promotion origin and residue safety framework, not human therapeutic data.
Pope et al., Endocrine Society Scientific Statement2014
Frames potent non-aromatizing 19-nor agents within documented AAS cardiovascular and psychiatric harm.